Enanta Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Enanta Pharmaceuticals generated cash of -$78,764,000, which is more than the previous year. Cash used in financing activities reached the amount of -$27,626,000 last year. Net change in cash is therefore -$48,155,000.
Cash Flow
| 2015 | 76.67M | -88.18M | 2.54M |
|---|---|---|---|
| 2016 | 35.80M | -43.66M | 2.70M |
| 2017 | 52.65M | -4.57M | 1.01M |
| 2018 | 29.22M | -35.40M | 4.40M |
| 2019 | 71.41M | -86.66M | 2.57M |
| 2020 | 7.08M | 19.83M | 8.98M |
| 2021 | -69.99M | 36.99M | 3.08M |
| 2022 | -84.78M | 54.89M | 20.03M |
| 2023 | -103.15M | -53.57M | 198.12M |
| 2024 | -78.76M | 58.23M | -27.62M |
ENTA Cash Flow Statement (2015 – 2024)
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 89.35M | 47.96M | 57.81M | 87.73M | 51.83M | 64.51M | 65.67M | 16.57M | 21.72M | 30.69M |
Operating activities | ||||||||||
Net income | -116.04M | -133.81M | -121.75M | -78.99M | -36.16M | 46.38M | 71.95M | 17.71M | 21.66M | 78.99M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 2.33M | 2.37M | 2.97M | 3.33M | 3.64M | 3.25M | 2.51M | 2.13M | 1.66M | 639K |
Stock-based compensation expense | 26.79M | 28.21M | 26.96M | 20.99M | 19.57M | 19.22M | 0 | 13.07M | 9.35M | 5.83M |
| Deferred income tax benefit | 26.79M | 28.21M | 26.96M | 20.99M | 19.57M | 19.22M | 0 | 13.07M | 9.35M | 5.83M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 973K | 9.41M | 3.25M | -84K | 27.82M | 15.89M | -56.59M | 2.22M | 2.44M | -13.56M |
Inventories | 0 | 0 | 0 | 0 | -16.3M | -6.48M | -6.42M | 18.63M | 1.87M | -3.37M |
Accounts payable | -414K | -1.15M | -4.63M | 3.77M | -883K | 1.79M | 1.31M | 633K | 1.45M | -543K |
Cash generated by operating activities | -78.76M | -103.15M | -84.78M | -69.99M | 7.08M | 71.41M | 29.22M | 52.65M | 35.80M | 76.67M |
Investing activities | ||||||||||
Purchases Of Investments | -307.28M | -373.39M | -171.44M | -307.34M | -338.55M | -549.31M | -293.10M | -251.37M | -192.42M | -196.30M |
Investments In Property Plant And Equipment | -17.94M | -9.05M | -2.12M | -750K | -1.44M | -5.41M | -2.98M | -2.50M | -4.73M | -2.33M |
Acquisitions Net | 0 | 44.52M | -54.89M | -37.74M | -21.27M | 86.66M | 0 | 0 | 0 | 9K |
Cash generated by investing activities | 58.23M | -53.57M | 54.89M | 36.99M | 19.83M | -86.66M | -35.40M | -4.57M | -43.66M | -88.18M |
Financing activities | ||||||||||
Common Stock Issued | 0 | 2.20M | 21.26M | 3.61M | 10.48M | 6.84M | 0 | 1.07M | 0 | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | -1.22M | -534K | -1.49M | -4.18M | 0 | -202K | 0 | 0 |
Repayments of term debt | -27.47M | 0 | 0 | 0 | 0 | -86K | -79K | -73K | -68K | 0 |
Cash used in financing activities | -27.62M | 198.12M | 20.03M | 3.08M | 8.98M | 2.57M | 4.40M | 1.01M | 2.70M | 2.54M |
Net Change In Cash | -48.15M | 41.39M | -9.85M | -29.92M | 35.90M | -12.67M | -1.77M | 49.09M | -5.14M | -8.97M |
Cash at end of period | 41.20M | 89.35M | 47.96M | 57.81M | 87.73M | 51.83M | 63.90M | 65.67M | 16.57M | 21.72M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |